Use of Biologics in Management of Atopic Eczema

23^rd World Dermatology Congress

June 20-21, 2022 | Paris, France

Adlene Adnan

University of Liverpool, United Kingdom

Posters & Accepted Abstracts: J Dermatol Dis

Abstract :

Introduction: Atopic dermatitis (AD) is a common inflammatory skin disease distinguished by intense pruritus, and excoriations. Most can be treated with topical agents. Some requires systemic therapy; however they have multiple adverse effects and limited efficacy. Dupilumab is the first targeted biologic agent, recently approved for the treatment of moderate-to-severe AD. It is a fully-human monoclonal antibody and blocks the shared IL-4 receptor which is proposed to be a critical pathway in allergic diseases. Methods: A search through Pubmed, Medline, DermNet, BAD Journals, Uptodate, and Embase was performed on use of dupilumab in treating moderate-to-severe AD. The articles found were reviewed and analysed. Results: The efficacies of different dupilumab doses were analysed and it showed that patients treated with dupilumab 300 mg weekly had similar clinical outcomes to those receiving 300 mg every alternate week. Therefore, NICE Guidance has recommended a dose of dupilumab every alternate week so as to be cost-effective in the NHS. Its safety profile is considered superior to that of immunosuppressive drugs, as it specifically blocks signals from IL-4 and IL-13 only. Common side effects of dupilumab are conjunctivitis, headaches and cold sores. Conclusion: The recommended criteria on indications to initiate Dupilumab treatment for moderateto-severe AD in adults is when the disease has not responded adequately to at least one other systemic therapy, or these are contraindicated or not tolerated. An adequate response is seen if there is at least 50% reduction in the EASI 50 at least a 4-point reduction in the DLQI from initiation of treatment.

Biography :

Adlene Adnan has completed her graduation from 2016 – 2019 - University of Liverpool, United Kingdom MBChB. Undergraduate entry programme. 2013 – 2016 - International Medical University, Malaysia (IMU) MBBS. Pre-clinical. Partner medical school program to University of Liverpool.